October 20th 2022 10:00 am EDT | 3:00 PM BST
Gene editing: Navigating IP, deal-making and regulatory challenges
Loading...
Gene editing technologies hold the promise to unlock enormous advances in treatment and even cures.
Investment activity in this area continues to accelerate, but questions remain around ownership of the technology and how to bring new treatments to patients. Join us as we explore what patent and regulatory decisions mean for future healthcare innovation.
Investment activity in this area continues to accelerate, but questions remain around ownership of the technology and how to bring new treatments to patients. Join us as we explore what patent and regulatory decisions mean for future healthcare innovation.
Topics that will be covered:
-
What are the most significant trends in gene editing R&D and deal-making activity, and how do we expect that to evolve over the next 5-10 years?
-
How will the recent USPTO decision on CRISPR impact freedom to operate in the United States, and will this have ripple effects in other regions like Europe and Asia-Pacific?
-
What regulatory and ethical challenges will stakeholders need to factor in at the earliest stages of development?
-
How will this decision impact investment strategies and deal-making activity?
-
What types of emerging data and methods are companies using to provide strategic guidance and make decisions around gene editing and other emerging healthcare innovations?
Featured speakers
James Fry
Head of Life Sciences at Mills & Reeve LLP
Michael Arciero
Vice President IP & Commercial Development at ERS Genomics
Mike Ward
Global Head of Life Sciences & Healthcare Thought Leadership at Clarivate
Dr. Tobias Brambrink
J.D. VP, Intellectual Property at Chroma Medicine
Register below and we'll send the details straight to your inbox.
